• Project Title: Eligibility of miRNAs modified by docetaxel in prostate cancer cells to plasma biomarkers in patients responsive or no more responsive to docetaxel
• Funding: ITT Istituto Toscano Tumori
• Partners: CNR-IFC (Pisa), CNR-IIT (Pisa), AUSL n. 8 Arezzo
• Project Coordinator: Dr. Milena Rizzo (IFC-CNR)
• Duration: 3 years (2016-2018).
• Project value: 345,000 Euro
• AIM OF THE PROJECT: Several piece of evidence indicate that cancer cells are or become resistant to anticancer drugs depending on whether resistant cells were already existing or arising during treatment. Since experience shows that tumors often become resistant to anticancer drugs, new molecules and novel strategies are necessary to reduce the negative impact of resistance in tumor therapy. In this project we will study miRNA biomarkers for predicting resistance to docetaxel and cabazitaxel in Prostate cancer.

---

Last update: October 20th, 2015
[Marco's home page]